Live case transmission from St. Francis Hospital, The Heart Center
10:00 AM America/New_York
Allen Jeremias, MD, MSc, is the Director of Interventional Cardiology Research and Associate Director of the Cardiac Catheterization Laboratory at St. Francis Hospital in Roslyn, New York. He is also a member of the Cardiovascular Research Foundation in New York City where he currently serves as the Director of the Physiology Core Laboratory. He completed his medical training at The Cleveland Clinic Foundation, Stanford University School of Medicine, and Harvard Medical School. He has been a high volume interventional cardiologist since 2006 and recognized as a Top Doctor in the New York Metro Area by Castle Connolly. Dr. Jeremias has significantly contributed to advancing the field of interventional cardiology and he is considered one of the foremost authorities in coronary physiology and intravascular imaging. He is a co-director of the annual St. Francis Intravascular Imaging and Coronary Physiology Workshop, teaching physicians around the world on “Precision Angioplasty”. Dr. Jeremias is presently engaged in a major global study that could change the path of treating clogged arteries. Known as the ILUMIEN IV trial, this major clinical study is evaluating Optical Coherence Tomography (OCT) to guide coronary stent placement. He is also the principal investigator of DEFINE PCI, an international study on assessing the improvement in blood flow after stent placement for severe coronary blockages.
An internationally recognized interventional cardiologist, Dr. Moses has performed more than 15,000 interventional procedures, authored over 600 publications, and served as lead investigator for numerous national and international clinical studies that have demonstrated the effectiveness and safety of coronary stent placement. In 2002, Dr. Moses was the lead investigator on a large clinical trial, the first in the U.S. that demonstrated the enormous benefit that led to FDA approval of the first drug-coated stent now used in the majority of interventional procedures in the U.S. Most recently in on the Executive Committee of PARTNER trial; they brought the first transcatheter aortic valve to clinical use in the U.S. He currently serves as Director of Interventional Cardiovascular Therapeutics at Columbia University Medical Center and as Director of Advanced Cardiac Interventions at St Francis Hospital and Heart Center in Roslyn, NY. He is also a pioneer in developing approaches involving minimally invasive surgery, angioplasty, gene therapy, novel imaging technologies and various support devices that allow for wider application of interventional cardiovascular procedures.
Ajay J. Kirtane, MD, SM, is a Professor of Medicine at Columbia University Medical Center and Director of the Cardiac Catheterization Laboratories at New York Presbyterian Hospital. Dr. Kirtane is a graduate of Princeton University and Columbia University College of Physicians and Surgeons, and completed his residency in Internal Medicine at the University of California – San Francisco. Dr. Kirtane is a practicing Cardiologist with an interest in coronary and peripheral intervention and assumed the directorship of the NYP/Columbia cardiac catheterization laboratories in 2015. In addition to his clinical commitments at CUMC, Dr. Kirtane has a strong interest in clinical education and research, serving as Chief Academic Officer of the Center for Interventional Vascular Therapy. On the national and international level, he is a co-director of the Cardiovascular Research Foundation’s Transcatheter Cardiovascular Therapeutics meeting, has served as a director of several international, national, and regional educational meetings, and has participated on the program committees for the scientific sessions of both the American College of Cardiology and American Heart Association. Dr. Kirtane’s research interests are in clinical trial methodology and outcomes of device-based and pharmacologic interventions in Interventional Cardiology. He has authored/co-authored >150 original manuscripts and >50 reviews and chapters including the “Coronary Stenting” chapters of the two most widely used textbooks in Interventional Cardiology.
Ziad Ali is the Director of the DeMatteis Cardiovascular Institute, Director of Investigational Interventional Cardiology, and Director of Cardio-nephrology at St Francis Hospital & Heart Center in New York. He is also Director of the Angiographic Core Laboratory at Cardiovascular Research Foundation and Associate Professor of Medicine at Columbia University Medical Center. His clinical research interests focus on the use of intravascular imaging and physiology technologies such as optical coherence tomography, intravascular ultrasound, and flow wire assessment to optimize coronary interventions, for which he has served as a Global principal investigator on a number of trials. Dr. Ali is also a recognized innovator, playing an integral role in the development of the Resting Full-Cycle Ratio (RFR) and Shockwave intravascular lithotripsy. Clinically Dr. Ali developed pioneering techniques to perform vascular interventions without contrast administration, including IVUS-guided zero-contrast PCI and OCT using saline flush media, protecting patients with advanced kidney disease from acute kidney injury and the need for dialysis.
Dr. Evan Shlofmitz is an Interventional Cardiologist and the Director of Intravascular Imaging at St. Francis Hospital - The Heart Center in Roslyn, NY. He completed a fellowship in Interventional Cardiology at Georgetown University/MedStar Washington Hospital Center. He previously completed an Intravascular Imaging and Physiology fellowship at the Cardiovascular Research Foundation (CRF) and Columbia University Medical Center (CUMC), a Cardiovascular Disease fellowship at Northwell Health and served as Chief Resident for Internal Medicine at New York Presbyterian Queens. Dr. Shlofmitz has a strong interest in clinical education and research, lecturing internationally. He is a course director for Optimizing PCI (O-PCI) and CRT's Imaging & Physiology course and serves on SCAI's Ischemic Heart Disease Council and the steering committee for the IMPROVE trial. His research interests have centered on intravascular imaging, the treatment of calcified coronary artery disease, in-stent restenosis and the optimization of stent implantation, with more than 125 publications in peer-reviewed journals.
Dr. Karmpaliotis is a member of the Center for Interventional Vascular Therapy at Columbia University Medical Center. Dr. Karmpaliotis specializes in advanced, complex coronary intervention. He brings a wealth of experience in percutaneous coronary interventions. Dr. Karmpaliotis graduated from the University of Athens School of Health Sciences and trained at the prestigious Beth Israel Deaconess Medical Center at Harvard Medical School. Dr. Karmpaliotis was instrumental in building a world-class interventional cardiology program at Piedmont Heart Center in Atlanta, Georgia and has contributed to building one of the largest complex PCI programs in the world at CUMC. He also serves as the co-director of the US CTO Summit Dr. Karmpaliotis has served as principal investigator on more than 50 clinical trials, with special interest in the development of techniques for treating chronic total occlusions in coronary arteries.
David J. Cohen, MD, MSc is currently Director of Clinical and Outcomes Research at the Cardiovascular Research Foundation (New York, NY) and Director of Academic Affairs at St. Francis Hospital (Roslyn, NY). Previously, he was Professor of Medicine at the University of Missouri–Kansas City and Director of Cardiovascular Research and Medical Director of Health Economics and Technology Assessment at Saint Luke’s Mid America Heart Institute. Heart Institute where he continues to direct the Health Economics and Technology Assessment Group. Dr. Cohen earned his M.D. at Harvard Medical School and his Master's degree in Health Policy at the Harvard School of Public Health. He did his clinical training at Brigham and Women's Hospital and was a clinical and research fellow in cardiology at Beth Israel Hospital for five years. Dr. Cohen is a practicing interventional cardiologist with a focus on structural and valvular heart disease. His research focuses on the application of formal cost-effectiveness methodology to novel interventions for cardiovascular disease (CVD), the extension of traditional cardiovascular outcomes research to include patient-centered outcomes, and the development and evaluation of instruments for assessing CVD patients’ health status and preferences. He is also active in research to determine the short- and long-term outcomes of new devices for percutaneous coronary revascularization and identifying the optimal target populations and techniques for these devices. Dr. Cohen has published more than 500 original articles in leading journals, including the New England Journal of Medicine, Lancet, JAMA, Circulation, and the Journal of the American College. Dr. Cohen serves on the editorial board for the American Heart Journal, JACC Interventions, and Circulation and reviews for the American Journal of Cardiology, Journal of the American College of Cardiology, New England Journal of Medicine, JAMA, and Medical Decision Making.